Actavis Inc. clinical trials

Acquired by Teva Pharmaceutical Industries, Ltd., Aug 2, 2016 · source ↗

The registry lists 95 studies whose lead sponsor is Actavis Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 22, 2024.

Studies

Recruiting first, then most recently updated. Showing 50 of 95. List all 95 → · All Teva Pharmaceutical Industries, Ltd. studies →

• Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting ConditionsCompletedNCT01190748Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With AsthmaCompletedNCT03756883Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted after Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcgCompletedNCT03879837Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted after Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"CompletedNCT03954444Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted after Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Clinical Endpoint Study of Nepafenac 0.3% Opthalmic SuspensionCompletedNCT03499873Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted after Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic KeratosisCompletedNCT00948428Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Clinical Equivalence Study of Mometasone Nasal SprayCompletedNCT01850823Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic KeratosisCompletedNCT01962987Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Comparative Study to Evaluate KADIAN and Avinza in Healthy AdultsCompletedNCT00782548Phase 4

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to WaterCompletedNCT00768183Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle SprainCompletedNCT02324270Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne VulgarisCompletedNCT02651220Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthritis of the KneeCompletedNCT02495857Not applicable

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne VulgarisCompletedNCT02267746Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial RosaceaCompletedNCT02120924Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Clinical Endpoint Study of Ivermectin 1% CreamCompletedNCT02840461Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic DermatitisCompletedNCT02791308Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne VulgarisCompletedNCT02616614Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic KeratosisCompletedNCT02654769Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both EyesCompletedNCT02512042Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant WomenCompletedNCT02210689Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic KeratosisCompletedNCT03200912Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted after Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With RosaceaCompletedNCT02289352Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy VolunteersCompletedNCT00864604Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic VaginitisCompletedNCT03294538Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted after Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Clinical Endpoint Study of Ivermectin 0.5% LotionCompletedNCT03301649Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted after Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic KeratosesCompletedNCT02120898Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's DiarrheaCompletedNCT02498418Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic ParticipantsCompletedNCT02495168Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With RosaceaCompletedNCT03287791Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted after Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic KeratosisCompletedNCT02616601Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• The Dose-response "Pilot" Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult SubjectsCompletedNCT00864240Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult SubjectsCompletedNCT00864500Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy SubjectsWithdrawnNCT01760980Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in AsthmaticsWithdrawnNCT02496715Phase 3

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed ConditionsCompletedNCT01190761Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting ConditionsCompletedNCT01188031Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting ConditionsCompletedNCT01188057Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting ConditionsCompletedNCT00863941Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Limited Food Effect Study of Gabapentin 800 mg TabletsCompletedNCT00865631Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting ConditionsCompletedNCT00864760Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting ConditionsCompletedNCT00865891Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult SubjectsCompletedNCT00865267Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting ConditionsCompletedNCT00864526Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• Single Dose Two-Way Crossover Fasted Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy VolunteersCompletedNCT00864968Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting ConditionsCompletedNCT00865657Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting ConditionsCompletedNCT00865839Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-fasting ConditionsCompletedNCT00864357Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting ConditionsCompletedNCT00865748Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.

• A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting ConditionsCompletedNCT00865696Phase 1

  Sponsor listed in the registry: Actavis Inc. · First submitted before Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd.